Transcend Medical Closes $22M to Improve Glaucoma Treatment
April 03, 2014
Transcend Medical, a company dedicated to the development of minimally invasive glaucoma interventions for the ophthalmic surgeon, has closed a $22 million Series C round of funding. Existing investors and an undisclosed global pharmaceutical and medical device company participated in the round. The funds will support completion of the company's U.S.-based, controlled COMPASS trial evaluating the CyPass Micro-Stent, a micro-invasive glaucoma implant. The follow-up period for the COMPASS trial is scheduled to complete in the second quarter of 2015.